Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 135

1.

Common Host Responses in Murine Aerosol Models of Infection Caused by Highly Virulent Gram-Negative Bacteria from the Genera Burkholderia, Francisella and Yersinia.

Clark GC, Essex-Lopresti A, Moore KA, Williamson ED, Lukaszewski R, Paszkiewicz K, David J.

Pathogens. 2019 Sep 21;8(4). pii: E159. doi: 10.3390/pathogens8040159.

2.

Antibody-mediated protection against MERS-CoV in the murine model.

New RRC, Moore BD, Butcher W, Mahood R, Lever MS, Smither S, O'Brien L, Weller SA, Bayliss M, Gibson LCD, Macleod C, Bogus M, Harvey R, Almond N, Williamson ED.

Vaccine. 2019 Jul 9;37(30):4094-4102. doi: 10.1016/j.vaccine.2019.05.074. Epub 2019 Jun 6.

3.

Predatory bacteria can protect SKH-1 mice from a lethal plague challenge.

Findlay JS, Flick-Smith HC, Keyser E, Cooper IA, Williamson ED, Oyston PCF.

Sci Rep. 2019 May 10;9(1):7225. doi: 10.1038/s41598-019-43467-1.

4.

CD200R deletion promotes a neutrophil niche for Francisella tularensis and increases infectious burden and mortality.

Casulli J, Fife ME, Houston SA, Rossi S, Dow J, Williamson ED, Clark GC, Hussell T, D'Elia RV, Travis MA.

Nat Commun. 2019 May 9;10(1):2121. doi: 10.1038/s41467-019-10156-6.

5.

Vaccines for emerging pathogens: from research to the clinic.

Williamson ED.

Clin Exp Immunol. 2019 May;196(2):155-156. doi: 10.1111/cei.13303.

6.

Use of bioengineered human commensal gut bacteria-derived microvesicles for mucosal plague vaccine delivery and immunization.

Carvalho AL, Miquel-Clopés A, Wegmann U, Jones E, Stentz R, Telatin A, Walker NJ, Butcher WA, Brown PJ, Holmes S, Dennis MJ, Williamson ED, Funnell SGP, Stock M, Carding SR.

Clin Exp Immunol. 2019 Jun;196(3):287-304. doi: 10.1111/cei.13301. Epub 2019 Apr 15.

7.

Vaccines for emerging pathogens: prospects for licensure.

Williamson ED, Westlake GE.

Clin Exp Immunol. 2019 Apr 11. doi: 10.1111/cei.13284. [Epub ahead of print] Review.

PMID:
30972733
8.

Exploitation of the bilosome platform technology to formulate antibiotics and enhance efficacy of melioidosis treatments.

D'Elia RV, Woods S, Butcher W, McGahon J, Khadke S, Perrie Y, Williamson ED, Roberts CW.

J Control Release. 2019 Mar 28;298:202-212. doi: 10.1016/j.jconrel.2019.02.002. Epub 2019 Feb 4.

9.

Dual route vaccination for plague with emergency use applications.

Moore BD, New RRC, Butcher W, Mahood R, Steward J, Bayliss M, MacLeod C, Bogus M, Williamson ED.

Vaccine. 2018 Aug 16;36(34):5210-5217. doi: 10.1016/j.vaccine.2018.06.039. Epub 2018 Jul 14.

10.

Deep Sequencing of RNA from Blood and Oral Swab Samples Reveals the Presence of Nucleic Acid from a Number of Pathogens in Patients with Acute Ebola Virus Disease and Is Consistent with Bacterial Translocation across the Gut.

Carroll MW, Haldenby S, Rickett NY, Pályi B, Garcia-Dorival I, Liu X, Barker G, Bore JA, Koundouno FR, Williamson ED, Laws TR, Kerber R, Sissoko D, Magyar N, Di Caro A, Biava M, Fletcher TE, Sprecher A, Ng LFP, Rénia L, Magassouba N, Günther S, Wölfel R, Stoecker K, Matthews DA, Hiscox JA.

mSphere. 2017 Aug 23;2(4). pii: e00325-17. doi: 10.1128/mSphereDirect.00325-17. eCollection 2017 Jul-Aug.

11.

Targeting Bacillus anthracis toxicity with a genetically selected inhibitor of the PA/CMG2 protein-protein interaction.

Male AL, Forafonov F, Cuda F, Zhang G, Zheng S, Oyston PCF, Chen PR, Williamson ED, Tavassoli A.

Sci Rep. 2017 Jun 8;7(1):3104. doi: 10.1038/s41598-017-03253-3.

12.

Interference of the T Cell and Antigen-Presenting Cell Costimulatory Pathway Using CTLA4-Ig (Abatacept) Prevents Staphylococcal Enterotoxin B Pathology.

Whitfield SJC, Taylor C, Risdall JE, Griffiths GD, Jones JTA, Williamson ED, Rijpkema S, Saraiva L, Vessillier S, Green AC, Carter AJ.

J Immunol. 2017 May 15;198(10):3989-3998. doi: 10.4049/jimmunol.1601525. Epub 2017 Mar 20.

13.

Developmental Psychopathology: Risk and Resilience in the Transition to Young Adulthood.

Leebens PK, Williamson ED.

Child Adolesc Psychiatr Clin N Am. 2017 Apr;26(2):143-156. doi: 10.1016/j.chc.2016.12.001. Review.

PMID:
28314447
14.

A comparison of host gene expression signatures associated with infection in vitro by the Makona and Ecran (Mayinga) variants of Ebola virus.

Bosworth A, Dowall SD, Garcia-Dorival I, Rickett NY, Bruce CB, Matthews DA, Fang Y, Aljabr W, Kenny J, Nelson C, Laws TR, Williamson ED, Stewart JP, Carroll MW, Hewson R, Hiscox JA.

Sci Rep. 2017 Feb 27;7:43144. doi: 10.1038/srep43144.

15.

Transcriptomic signatures differentiate survival from fatal outcomes in humans infected with Ebola virus.

Liu X, Speranza E, Muñoz-Fontela C, Haldenby S, Rickett NY, Garcia-Dorival I, Fang Y, Hall Y, Zekeng EG, Lüdtke A, Xia D, Kerber R, Krumkamp R, Duraffour S, Sissoko D, Kenny J, Rockliffe N, Williamson ED, Laws TR, N'Faly M, Matthews DA, Günther S, Cossins AR, Sprecher A, Connor JH, Carroll MW, Hiscox JA.

Genome Biol. 2017 Jan 19;18(1):4. doi: 10.1186/s13059-016-1137-3.

16.

Life sciences today and tomorrow: emerging biotechnologies.

Williamson ED.

Crit Rev Biotechnol. 2017 Aug;37(5):553-565. doi: 10.1080/07388551.2016.1201455. Epub 2016 Jul 3. Review.

PMID:
27373876
17.

CD4+ T Cells Targeting Dominant and Cryptic Epitopes from Bacillus anthracis Lethal Factor.

Ascough S, Ingram RJ, Chu KK, Musson JA, Moore SJ, Gallagher T, Baillie L, Williamson ED, Robinson JH, Maillere B, Boyton RJ, Altmann DM.

Front Microbiol. 2016 Jan 5;6:1506. doi: 10.3389/fmicb.2015.01506. eCollection 2015.

18.

Anthrax prophylaxis: recent advances and future directions.

Williamson ED, Dyson EH.

Front Microbiol. 2015 Sep 24;6:1009. doi: 10.3389/fmicb.2015.01009. eCollection 2015. Review.

19.

Label-free Fab and Fc affinity/avidity profiling of the antibody complex half-life for polyclonal and monoclonal efficacy screening.

Read T, Olkhov RV, Williamson ED, Shaw AM.

Anal Bioanal Chem. 2015 Sep;407(24):7349-57. doi: 10.1007/s00216-015-8897-6. Epub 2015 Jul 19.

PMID:
26187320
20.

Vaccines and therapies for biodefence agents.

Tree JA, Williamson ED, Rowland CA, Pitt LM.

J Immunol Res. 2015;2015:537319. doi: 10.1155/2015/537319. Epub 2015 Mar 8. No abstract available.

21.

Kinetic epitope mapping of monoclonal antibodies raised against the Yersinia pestis virulence factor LcrV.

Read T, Olkhov RV, Williamson ED, Shaw AM.

Biosens Bioelectron. 2015 Mar 15;65:47-53. doi: 10.1016/j.bios.2014.09.090. Epub 2014 Oct 5.

PMID:
25461137
22.

Control of intracellular Francisella tularensis by different cell types and the role of nitric oxide.

Newstead SL, Gates AJ, Hartley MG, Rowland CA, Williamson ED, Lukaszewski RA.

J Immunol Res. 2014;2014:694717. doi: 10.1155/2014/694717. Epub 2014 Jul 21.

23.

Protection against experimental melioidosis following immunisation with a lipopolysaccharide-protein conjugate.

Scott AE, Ngugi SA, Laws TR, Corser D, Lonsdale CL, D'Elia RV, Titball RW, Williamson ED, Atkins TP, Prior JL.

J Immunol Res. 2014;2014:392170. doi: 10.1155/2014/392170. Epub 2014 May 7.

24.

Burkholderia pseudomallei capsular polysaccharide conjugates provide protection against acute melioidosis.

Scott AE, Burtnick MN, Stokes MG, Whelan AO, Williamson ED, Atkins TP, Prior JL, Brett PJ.

Infect Immun. 2014 Aug;82(8):3206-13. doi: 10.1128/IAI.01847-14. Epub 2014 May 27.

25.

Anthrax lethal factor as an immune target in humans and transgenic mice and the impact of HLA polymorphism on CD4+ T cell immunity.

Ascough S, Ingram RJ, Chu KK, Reynolds CJ, Musson JA, Doganay M, Metan G, Ozkul Y, Baillie L, Sriskandan S, Moore SJ, Gallagher TB, Dyson H, Williamson ED, Robinson JH, Maillere B, Boyton RJ, Altmann DM.

PLoS Pathog. 2014 May 1;10(5):e1004085. doi: 10.1371/journal.ppat.1004085. eCollection 2014 May.

26.

Proteomic analysis of Bacillus subtilis strains engineered for improved production of heterologous proteins.

Pohl S, Bhavsar G, Hulme J, Bloor AE, Misirli G, Leckenby MW, Radford DS, Smith W, Wipat A, Williamson ED, Harwood CR, Cranenburgh RM.

Proteomics. 2013 Nov;13(22):3298-308. doi: 10.1002/pmic.201300183. Epub 2013 Oct 27.

PMID:
24115457
27.

Prophylaxis and therapy of plague.

Oyston PC, Williamson ED.

Expert Rev Anti Infect Ther. 2013 Aug;11(8):817-29. doi: 10.1586/14787210.2013.814432. Review.

PMID:
23977937
28.

Protection against experimental melioidosis following immunization with live Burkholderia thailandensis expressing a manno-heptose capsule.

Scott AE, Laws TR, D'Elia RV, Stokes MG, Nandi T, Williamson ED, Tan P, Prior JL, Atkins TP.

Clin Vaccine Immunol. 2013 Jul;20(7):1041-7. doi: 10.1128/CVI.00113-13. Epub 2013 May 15.

29.

Exposure to anthrax toxin alters human leucocyte expression of anthrax toxin receptor 1.

Ingram RJ, Harris A, Ascough S, Metan G, Doganay M, Ballie L, Williamson ED, Dyson H, Robinson JH, Sriskandan S, Altmann DM.

Clin Exp Immunol. 2013 Jul;173(1):84-91. doi: 10.1111/cei.12090.

30.

Protecting against plague: towards a next-generation vaccine.

Williamson ED, Oyston PC.

Clin Exp Immunol. 2013 Apr;172(1):1-8. doi: 10.1111/cei.12044. Review.

31.

Conjugation of Y. pestis F1-antigen to gold nanoparticles improves immunogenicity.

Gregory AE, Williamson ED, Prior JL, Butcher WA, Thompson IJ, Shaw AM, Titball RW.

Vaccine. 2012 Nov 6;30(48):6777-82. doi: 10.1016/j.vaccine.2012.09.021. Epub 2012 Sep 18.

32.

Modern Advances against Plague.

Oyston PC, Williamson ED.

Adv Appl Microbiol. 2012;81:209-41. doi: 10.1016/B978-0-12-394382-8.00006-X.

PMID:
22958531
33.

Recombinant protective antigen anthrax vaccine improves survival when administered as a postexposure prophylaxis countermeasure with antibiotic in the New Zealand white rabbit model of inhalation anthrax.

Leffel EK, Bourdage JS, Williamson ED, Duchars M, Fuerst TR, Fusco PC.

Clin Vaccine Immunol. 2012 Aug;19(8):1158-64. doi: 10.1128/CVI.00240-12. Epub 2012 Jun 13.

34.

Electrochemical detection of the binding of Bacillus anthracis protective antigen (PA) to the membrane receptor on macrophages through release of nitric oxide.

Trouillon R, Williamson ED, Saint RJ, O'Hare D.

Biosens Bioelectron. 2012 Oct-Dec;38(1):138-44. doi: 10.1016/j.bios.2012.05.012. Epub 2012 May 24.

PMID:
22672762
35.

The natural history and incidence of Yersinia pestis and prospects for vaccination.

Williamson ED, Oyston PC.

J Med Microbiol. 2012 Jul;61(Pt 7):911-8. doi: 10.1099/jmm.0.037960-0. Epub 2012 Mar 22. Review.

PMID:
22442294
36.

The role of immune correlates and surrogate markers in the development of vaccines and immunotherapies for plague.

Williamson ED.

Adv Prev Med. 2012;2012:365980. doi: 10.1155/2012/365980. Epub 2011 Sep 29.

37.

Recombinant (F1+V) vaccine protects cynomolgus macaques against pneumonic plague.

Williamson ED, Packer PJ, Waters EL, Simpson AJ, Dyer D, Hartings J, Twenhafel N, Pitt ML.

Vaccine. 2011 Jun 24;29(29-30):4771-7. doi: 10.1016/j.vaccine.2011.04.084. Epub 2011 May 12.

PMID:
21570437
38.

Psychotropic medications in autism: practical considerations for parents.

Williamson ED, Martin A.

J Autism Dev Disord. 2012 Jun;42(6):1249-55. doi: 10.1007/s10803-010-1144-2. Review.

PMID:
21170674
39.

Repertoire of HLA-DR1-restricted CD4 T-cell responses to capsular Caf1 antigen of Yersinia pestis in human leukocyte antigen transgenic mice.

Musson JA, Ingram R, Durand G, Ascough S, Waters EL, Hartley MG, Robson T, Maillere B, Williamson ED, Sriskandan S, Altmann D, Robinson JH.

Infect Immun. 2010 Oct;78(10):4356-62. doi: 10.1128/IAI.00195-10. Epub 2010 Jul 26.

40.

Predictive models and correlates of protection for testing biodefence vaccines.

Williamson ED, Duchars MG, Kohberger R.

Expert Rev Vaccines. 2010 May;9(5):527-37. doi: 10.1586/erv.10.22. Review.

PMID:
20450327
41.

An epitope of Bacillus anthracis protective antigen that is cryptic in rabbits may be immunodominant in humans.

Ingram RJ, Chu KK, Metan G, Maillere B, Doganay M, Ozkul Y, Dyson H, Williamson ED, Baillie L, Kim LU, Ascough S, Sriskandan S, Altmann DM.

Infect Immun. 2010 May;78(5):2353; author reply 2353-4. doi: 10.1128/IAI.00072-10. No abstract available.

42.

Natural exposure to cutaneous anthrax gives long-lasting T cell immunity encompassing infection-specific epitopes.

Ingram RJ, Metan G, Maillere B, Doganay M, Ozkul Y, Kim LU, Baillie L, Dyson H, Williamson ED, Chu KK, Ascough S, Moore S, Huwar TB, Robinson JH, Sriskandan S, Altmann DM.

J Immunol. 2010 Apr 1;184(7):3814-21. doi: 10.4049/jimmunol.0901581. Epub 2010 Mar 5.

43.

Plague.

Williamson ED.

Vaccine. 2009 Nov 5;27 Suppl 4:D56-60. doi: 10.1016/j.vaccine.2009.07.068. Review.

PMID:
19837288
44.

N255 is a key residue for recognition by a monoclonal antibody which protects against Yersinia pestis infection.

Hill J, Leary S, Smither S, Best A, Pettersson J, Forsberg A, Lingard B, Lipka A, Brown KA, Williamson ED, Titball RW.

Vaccine. 2009 Nov 23;27(50):7073-9. doi: 10.1016/j.vaccine.2009.09.061. Epub 2009 Sep 26.

PMID:
19786138
45.

Enhanced vaccine antigen delivery by Salmonella using antibiotic-free operator-repressor titration-based plasmid stabilisation compared to chromosomal integration.

Leckenby MW, Spear AM, Neeson BN, Williamson ED, Cranenburgh RM, Atkins HS.

Microb Pathog. 2009 Apr;46(4):201-6. doi: 10.1016/j.micpath.2009.01.001. Epub 2009 Jan 24.

PMID:
19490834
46.

Intranasal administration of influenza vaccines: current status.

Eyles JE, Williamson ED, Alpar HO.

BioDrugs. 2000 Jan;13(1):35-59.

PMID:
18034512
47.

Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax.

Albrecht MT, Li H, Williamson ED, LeButt CS, Flick-Smith HC, Quinn CP, Westra H, Galloway D, Mateczun A, Goldman S, Groen H, Baillie LW.

Infect Immun. 2007 Nov;75(11):5425-33. Epub 2007 Jul 23.

48.

The fraction 1 and V protein antigens of Yersinia pestis activate dendritic cells to induce primary T cell responses.

Kingston R, Burke F, Robinson JH, Bedford PA, Jones SM, Knight SC, Williamson ED.

Clin Exp Immunol. 2007 Sep;149(3):561-9. Epub 2007 Jul 23.

49.

Immunogenicity of the rF1+rV vaccine for plague with identification of potential immune correlates.

Williamson ED, Flick-Smith HC, Waters E, Miller J, Hodgson I, Le Butt CS, Hill J.

Microb Pathog. 2007 Jan;42(1):11-21. Epub 2006 Nov 14.

PMID:
17107769
50.

A biocompatible microdevice for core body temperature monitoring in the early diagnosis of infectious disease.

Williamson ED, Savage VL, Lingard B, Russell P, Scott EA.

Biomed Microdevices. 2007 Feb;9(1):51-60.

PMID:
17106641

Supplemental Content

Loading ...
Support Center